Phase I monoclonal antibodies clinical trials grew at fastest rate, 2007–2016

GlobalData compiled a summary of global clinical trials in monoclonal antibodies (mAbs) in the past ten years.

In GlobalData’s White Paper: Global Trends in Monoclonal Antibodies Clinical Trials – A 10-Year Retrospective, 2007–2016, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively. Overall, Phase II trials outnumbered all other trials by contributing between 31% and 46% across the period. The share of Phase I trials started at 18% in 2007 and increased to 27% by 2016, as shown in Figure 1. The share of Phase III trials remained flat at an average of 24% across the 10-year period, whereas Phase IV trials decreased in share from 13% to 12% in the first and last years, respectively. Phase I studies grew at a faster rate than all other Phases across the 10-year period, at a Compound Annual Growth Rate (CAGR) of 16%, followed by Phase III at a CAGR of 10%, Phase II at a CAGR of 5%, and Phase IV at a CAGR of 4%.